New insights into immune reconstitution inflammatory syndrome of the central nervous system

Current Opinion in HIV and AIDS

Volumn 9, Issue 6, 2014, Pages 572-578

  Johnson, Tory P ^a   Nath, Avindra ^a  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

Antiretrovirals; Brain; Encephalitis; HIV associated neurocognitive disorders; Tat

Indexed keywords

CORTICOSTEROID; NATALIZUMAB; ANTIRETROVIRUS AGENT;

CENTRAL NERVOUS SYSTEM DISEASE; ENCEPHALITIS; HIV ASSOCIATED DEMENTIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; INCIDENCE; MORTALITY; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; REVIEW; RISK FACTOR; BRAIN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; VIROLOGY;

ANTI-RETROVIRAL AGENTS; BRAIN; CENTRAL NERVOUS SYSTEM DISEASES; HIV INFECTIONS; HUMANS; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME;

EID: 84925521572     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0000000000000107     Document Type: Review

References (76)

1. French MA. Disorders of immune reconstitution in patients with HIV infection responding to antiretroviral therapy. Curr HIV/AIDS Rep 2007; 4:16-21.
2. Shelburne SA 3rd, Hamill RJ. The immune reconstitution inflammatory syndrome. AIDS Rev 2003; 5:67-79.
3. Shelburne SA, Visnegarwala F, Darcourt J, et al. Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy. AIDS 2005; 19:399-406.
4. Ndumbi P, Gillis J, Raboud J, et al. Characteristics and determinants of T-cell phenotype normalization in HIV-1-infected individuals receiving long-term antiretroviral therapy. HIV Med 2014; 15:153-164.
5. Sinclair E, Ronquillo R, Lollo N, et al. Antiretroviral treatment effect on immune activation reduces cerebrospinal fluid HIV-1 infection. J Acquir Immune Defic Syndr 2008; 47:544-552.
6. Singer EJ, Valdes-Sueiras M, Commins DL, et al. HIV stroke risk: evidence and implications. Ther Adv Chronic Dis 2013; 4:61-70.
7. Carugati M, Franzetti M, Torre A, et al. Systemic lupus erythematosus and HIV infection: a whimsical relationship. Reports of two cases and review of the literature. Clin Rheumatol 2013; 32:1399-1405.
8. Iordache L, Launay O, Bouchaud O, et al. Autoimmune diseases in HIVinfected patients: 52 cases and literature review. Autoimmun Rev 2014; 13:850-857.
9. Heaton RK, Franklin DR, Ellis RJ, et al. HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol 2011; 17:3-16.
10. Rao VR, Ruiz AP, Prasad VR. Viral and cellular factors underlying neuropathogenesis in HIV associated neurocognitive disorders (HAND). AIDS Res Ther 2014; 11:13.
11. Helleberg M, Gerstoft J, Afzal S, et al. Risk of cancer among HIV-infected individuals compared to the background population: impact of smoking and HIV. AIDS 2014; 28:1499-1508.
12. Patel P, Hanson DL, Sullivan PS, et al. Incidence of types of cancer among HIV-infected persons compared with the general population in the United States. Ann Intern Med 2008; 148:728-736.
13. Deeks SG, Phillips AN. HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity. BMJ 2009; 338:a3172.
14. Guaraldi G, Orlando G, Zona S, et al. Premature age-related comorbidities among HIV-infected persons compared with the general population. Clin Infect Dis 2011; 53:1120-1126.
15. Tsoukas C. Immunosenescence and aging in HIV. Curr Opin HIV AIDS 2014; 9:398-404.
16. Stevenson M. CROI 2014 basic science review. Top Antivir Med 2014; 22:574-578.
17. Taylor BS, Shalev N, Wilkin TJ. CROI 2014 advances in antiretroviral therapy. Top Antivir Med 2014; 22:616-631.
18. Novis CL, Archin NM, Buzon MJ, et al. Reactivation of latent HIV-1 in central memory CD4(+) T cells through TLR-1/2 stimulation. Retrovirology 2013; 10:119.
19. Sgarbanti M, Battistini A. Therapeutics for HIV-1 reactivation from latency. Curr Opin Virol 2013; 3:394-401.
20. Nath A, Clements JE. Eradication of HIV from the brain: reasons for pause. AIDS 2011; 25:577-580.
21. Muller M, Wandel S, Colebunders R, et al. Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis. Lancet Infect Dis 2010; 10:251-261.
22. Hoyo-Ulloa I, Belaunzaran-Zamudio PF, Crabtree-Ramirez B, et al. Impact of the immune reconstitution inflammatory syndrome (IRIS) on mortality and morbidity in HIV-infected patients in Mexico. Int J Infect Dis 2011; 15:e408-e414.
23. Letang E, Miro JM, Nhampossa T, et al. Incidence and predictors of immune reconstitution inflammatory syndrome in a rural area of Mozambique. PLoS One 2011; 6:e16946.
24. McCombe JA, Auer RN, Maingat FG, et al. Neurologic immune reconstitution inflammatory syndrome in HIV/AIDS: outcome and epidemiology. Neurology 2009; 72:835-841.
25. Asselman V, Thienemann F, Pepper DJ, et al. Central nervous system disorders after starting antiretroviral therapy in South Africa. AIDS 2010; 24:2871-2876.
26. Dai L, Mahajan SD, Guo C, et al. Spectrum of central nervous system disorders in hospitalized HIV/AIDS patients at a major HIV/AIDS referral center in Beijing China. J Neurol Sci 2014; 342:88-92.
27. Narendran G, Andrade BB, Porter BO, et al. Paradoxical tuberculosis immune reconstitution inflammatory syndrome (TB-IRIS) in HIV patients with culture confirmed pulmonary tuberculosis in India and the potential role of IL-6 in prediction. PLoS One 2013; 8:e63541.
28. Pepper DJ, Marais S, Maartens G, et al. Neurologic manifestations of paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome: a case series. Clin Infect Dis 2009; 48:e96-e107.
29. Riveiro-Barciela M, Falco V, Burgos J, et al. Neurological opportunistic infections and neurological immune reconstitution syndrome: impact of one decade of highly active antiretroviral treatment in a tertiary hospital. HIV Med 2013; 14:21-30.
30. Gkentzi D, Tebruegge M, Tudor-Williams G, et al. Incidence, spectrum and outcome of immune reconstitution syndrome in HIV-infected children following initiation of antiretroviral therapy. Pediatr Infect Dis J 2014. [Epub ahead of print]
31. Lortholary O, Fontanet A, Memain N, et al. Incidence and risk factors of immune reconstitution inflammatory syndrome complicating HIV-associated cryptococcosis in France. AIDS 2005; 19:1043-1049.
32. Rupali P, Mannam S, Bella A, et al. Risk factors for mortality in a south Indian population on generic antiretroviral therapy. J Assoc Physicians India 2012; 60:11-14.
33. Johnson T, Nath A. Immune reconstitution inflammatory syndrome and the central nervous system. Curr Opin Neurol 2011; 24:284-290.
34. Bahr N, Boulware DR, Marais S, et al. Central nervous system immune reconstitution inflammatory syndrome. Curr Infect Dis Rep 2013; 5:583-593.
35. Meintjes G, Lawn SD, Scano F, et al. Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resourcelimited settings. Lancet Infect Dis 2008; 8:516-523.
36. Boulware DR, Meya DB, Bergemann TL, et al. Clinical features and serum biomarkers in HIV immune reconstitution inflammatory syndrome after cryptococcal meningitis: a prospective cohort study. PLoS Med 2010; 7:e1000384.
37. Chang CC, Omarjee S, Lim A, et al. Chemokine levels and chemokine receptor expression in the blood and the cerebrospinal fluid of HIV-infected patients with cryptococcal meningitis and cryptococcosis-associated immune reconstitution inflammatory syndrome. J Infect Dis 2013; 208:1604-1612.
38. Corti M, Villafane M, Trione N, et al. Progressive multifocal leukoencephalopathy presenting as IRIS in an AIDS patient. A case report and literature review. Neuroradiol J 2013; 26:151-154.
39. Hirsch HH, Kardas P, Kranz D, Leboeuf C. The human JC polyomavirus (JCPyV): virological background and clinical implications. APMIS 2013; 121:685-727.
40. Tan K, Roda R, Ostrow L, et al. PML-IRIS in patients with HIV infection: clinical manifestations and treatment with steroids. Neurology 2009; 72:1458-1464.
41. Iro MA, Kirkham FJ, Macdonald JH, et al. Varicella zoster virus central nervous system immune reconstitution inflammatory syndrome presenting in a child. Pediatr Infect Dis J 2013; 32:1283-1284.
42. Newsome SD, Nath A. Varicella-zoster virus vasculopathy and central nervous system immune reconstitution inflammatory syndrome with human immunodeficiency virus infection treated with steroids. J Neurovirol 2009; 15:288-291.
43. Teo S, Raha D, Warren D, et al. Central nervous system-immune reconstitution inflammatory syndrome presenting as varicella zoster virusmediated vasculitis causing stroke. Int J STD AIDS 2014. [Epub ahead of print]
44. Karavellas MP, Lowder CY, Macdonald C, et al. Immune recovery vitritis associated with inactive cytomegalovirus retinitis: a new syndrome. Arch Ophthalmol 1998; 116:169-175.
45. Sugar EA, Jabs DA, Ahuja A, et al. Incidence of cytomegalovirus retinitis in the era of highly active antiretroviral therapy. Am J Ophthalmol 2012; 153:1016.e5-1024.e5.
46. Berkeley JL, Nath A, Pardo CA. Fatal immune reconstitution inflammatory syndrome with human immunodeficiency virus infection and Candida meningitis: case report and review of the literature. J Neurovirol 2008; 14:267-276.
47. Dinardo AR, Lewis DS, Koo HL, et al. Paradoxical immune reconstitution inflammatory syndrome due to toxoplasmic encephalitis: two cases and review of initiation of antiretroviral timing in toxoplasmic encephalitis IRIS. F1000Res 2013; 2:133.
48. Pfeffer G, Prout A, Hooge J, Maguire J. Biopsy-proven immune reconstitution syndrome in a patient with AIDS and cerebral toxoplasmosis. Neurology 2009; 73:321-322.
49. Tsambiras PE, Larkin JA, Houston SH. Case report. Toxoplasma encephalitis after initiation of HAART. AIDS Read 2001; 11:608-610; 615-616.
50. Hirnschall G, Harries AD, Easterbrook PJ, et al. The next generation of the World Health Organization's global antiretroviral guidance. J Int AIDS Soc 2013; 16:18757.
51. Boulware DR, Meya DB, Muzoora C, et al. Timing of antiretroviral therapy after diagnosis of cryptococcal meningitis. N Engl J Med 2014; 370:2487-2498.
52. Luetkemeyer AF, Kendall MA, Nyirenda M, et al. Tuberculosis immune reconstitution inflammatory syndrome in A5221 STRIDE: timing, severity, and implications for HIV-TB programs. J Acquir Immune Defic Syndr 2014; 65:423-428.
53. Torok ME, Yen NT, Chau TT, et al. Timing of initiation of antiretroviral therapy in human immunodeficiency virus (HIV)-associated tuberculous meningitis. Clin Infect Dis 2011; 52:1374-1383.
54. Hornik A, Rodriguez-Porcel F, Wallery S, et al. Late onset CNS immune reconstitution inflammatory syndrome in an immunocompetent patient. Front Neurol 2013; 4:12.
55. Langford TD, Letendre SL, Marcotte TD, et al. Severe, demyelinating leukoencephalopathy in AIDS patients on antiretroviral therapy. AIDS 2002; 16:1019-1029.
56. Huang W, Chen L, Zhang B, et al. PPAR agonist-mediated protection against HIV Tat-induced cerebrovascular toxicity is enhanced in MMP-9-deficient mice. J Cereb Blood Flow Metab 2014; 34:646-653.
57. Liu J, Xu C, Chen L, et al. Involvement of Kv1.3 and p38 MAPK signaling in HIV-1 glycoprotein 120-induced microglia neurotoxicity. Cell Death Dis 2012; 3:e254.
58. Shin AH, Thayer SA. Human immunodeficiency virus-1 protein Tat induces excitotoxic loss of presynaptic terminals in hippocampal cultures. Mol Cell Neurosci 2013; 54:22-29.
59. Spudich SS. CROI 2014 neurologic complications of HIV infection. Top Antivir Med 2014; 22:594-601.
60. Chan P, Brew BJ. HIV associated neurocognitive disorders in the modern antiviral treatment era: prevalence, characteristics, biomarkers, and effects of treatment. Curr HIV/AIDS Rep 2014; 11:317-324.
61. McArthur JC, Brew BJ, Nath A. Neurological complications of HIV infection. Lancet Neurol 2005; 4:543-555.
62. Abers MS, Shandera WX, Kass JS. Neurological and psychiatric adverse effects of antiretroviral drugs. CNS Drugs 2014; 28:131-145.
63. Akay C, Cooper M, Odeleye A, et al. Antiretroviral drugs induce oxidative stress and neuronal damage in the central nervous system. J Neurovirol 2014; 20:39-53.
64. Caniglia EC, Cain LE, Justice A, et al. Antiretroviral penetration into the CNS and incidence of AIDS-defining neurologic conditions. Neurology 2014; 83:134-141.
65. Gray F, Lescure FX, Adle-Biassette H, et al. Encephalitis with infiltration by CD8+ lymphocytes in HIV patients receiving combination antiretroviral treatment. Brain Pathol 2013; 23:525-533.
66. Lescure FX, Moulignier A, Savatovsky J, et al. CD8 encephalitis in HIVinfected patients receiving cART: a treatable entity. Clin Infect Dis 2013; 57:101-108.
67. Miller RF, Isaacson PG, Hall-Craggs M, et al. Cerebral CD8+ lymphocytosis in HIV-1 infected patients with immune restoration induced by HAART. Acta Neuropathol 2004; 108:17-23.
68. Lindzen E, Jewells V, Bouldin T, et al. Progressive tumefactive inflammatory central nervous system demyelinating disease in an acquired immunodeficiency syndrome patient treated with highly active antiretroviral therapy. J Neurovirol 2008; 14:569-573.
69. Roh D, Glenn MD, Petito CK, et al. Reversible severe encephalitis and word deafness following rapid immune reconstitution in AIDS: a case report. J Neurovirol 2013; 19:190-193.
70. Rushing EJ, Liappis A, Smirniotopoulos JD, et al. Immune reconstitution inflammatory syndrome of the brain: case illustrations of a challenging entity. J Neuropathol Exp Neurol 2008; 67:819-827.
71. Zaffiri L, Verma R, Struzzieri K, et al. Immune reconstitution inflammatory syndrome involving the central nervous system in a patient with HIV infection: a case report and review of literature. New Microbiol 2013; 36:89-92.
72. Johnson TP, Patel K, Johnson KR, et al. Induction of IL-17and nonclassical T-cell activation by HIV-Tat protein. Proc Natl Acad Sci U S A 2013; 110:13588-13593.
73. Mocroft A, Katlama C, Johnson AM, et al. AIDS across Europe 98 the EuroSIDA study. Lancet 2000; 356:291-296.
74. Grant I, Franklin DR Jr, Deutsch R, et al. Asymptomatic HIV-associated neurocognitive impairment increases risk for symptomatic decline. Neurology 2014; 82:2055-2062.
75. Ellis RJ, Badiee J, Vaida F, et al. CD4 nadir is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapy. AIDS 2011; 25:1747-1751.
76. Lublin FD, Reingold SC, Cohen JA, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology 2014; 83:278-286.